Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
RMA | Ann: Removal from Official List | 04/01/16 | 0 | 1.4K | |||
|
|||||||
RMA | Ann: Change of Share Registry | 05/11/15 | 0 | 1.2K | |||
|
|||||||
RMA | Ann: Restated Annual Report for the Year Ended 30 June 2015 | 05/11/15 | 0 | 1.1K | |||
|
|||||||
RMA | Ann: Extension of Time to Hold Annual General Meeting | 30/10/15 | 0 | 1.0K | |||
|
|||||||
RMA | Ann: Half Yearly Report and Accounts 2014 | 28/10/15 | 0 | 1.1K | |||
|
|||||||
RMA | Ann: Half Yearly Report and Accounts 2013 | 28/10/15 | 0 | 894 | |||
|
|||||||
RMA | Ann: Half Yearly Report and Accounts 2012 | 28/10/15 | 0 | 892 | |||
|
|||||||
RMA | Ann: Half Yearly Report and Accounts 2011 | 21/10/15 | 0 | 1.2K | |||
|
See All Discussions